A Combination of Gamma-Aminobutyric Acid, Glutamic Acid, Calcium, Thiamine, Pyridoxine, and Cyanocobalamin vs Ginger Extract in the Management of Chronic Motion Sickness: A Clinical Evaluation

IF 1.6 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Current Therapeutic Research-clinical and Experimental Pub Date : 2023-01-01 DOI:10.1016/j.curtheres.2023.100719

Carlos P. Nunes MD , Claudio Rodrigues MD , Mendel Suchmacher MD , Claudia Regina Esteves MD , Karin Gonçalves PhD , Hélio Rzetelna MD , Rafael V. Rodrigues MD , Luciana Regina de Vasconcelos MD , Spyros G.E. Mezitis MD, PhD , Heros Rabelo MSc , Renato Kaufmann MD, PhD , Fernanda Schwarz MChem , Henrique Goldberg (In Memoriam) MD , Aline Sintoveter MD , Mauro Geller MD, PhD

{"title":"A Combination of Gamma-Aminobutyric Acid, Glutamic Acid, Calcium, Thiamine, Pyridoxine, and Cyanocobalamin vs Ginger Extract in the Management of Chronic Motion Sickness: A Clinical Evaluation","authors":"Carlos P. Nunes MD , Claudio Rodrigues MD , Mendel Suchmacher MD , Claudia Regina Esteves MD , Karin Gonçalves PhD , Hélio Rzetelna MD , Rafael V. Rodrigues MD , Luciana Regina de Vasconcelos MD , Spyros G.E. Mezitis MD, PhD , Heros Rabelo MSc , Renato Kaufmann MD, PhD , Fernanda Schwarz MChem , Henrique Goldberg (In Memoriam) MD , Aline Sintoveter MD , Mauro Geller MD, PhD","doi":"10.1016/j.curtheres.2023.100719","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Motion sickness (kinetosis) is a common and temporarily incapacitant ailment, manageable with behavioral as well as pharmacological measures.</p></div><div><h3>Objective</h3><p>To assess the effectiveness and safety of a combination of gamma-aminobutyric acid, glutamic acid, calcium, thiamine, pyridoxine, and cyanocobalamin (Group A) (n = 170) and extract of <em>Zingiber officinale</em> (ginger) (Group B) (n = 165) in the management of chronic complaints consistent with motion sickness.</p></div><div><h3>Methods</h3><p>Both groups were tested according to the following end points, under self-paired as well as comparative study designs: reduction of ≥20 score points in the total motion sickness assessment questionnaire (MSAQ) score, percentage of patients presenting a reduction of the total MSAQ score, absolute MSAQ score reduction, physician's assessment scores, final overall assessment of study medication, and willingness to continue treatment. Safety was also evaluated.</p></div><div><h3>Results</h3><p>There was a statistically significant better performance under both study designs for Group A (<em>P</em> = 0.05 using different statistical tests) in all end points. Both regimens were safe, with different neurological and gastrointestinal tolerability outcomes.</p></div><div><h3>Conclusions</h3><p>Group A and Group B regimens were effective and safe in the management of chronic complaints consistent with motion sickness and the Group A regimen was more effective than Group B.</p></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"99 ","pages":"Article 100719"},"PeriodicalIF":1.6000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0011393X23000280/pdfft?md5=736b3f768b0eb7b2c6a3bb1f6b818624&pid=1-s2.0-S0011393X23000280-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Therapeutic Research-clinical and Experimental","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0011393X23000280","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Motion sickness (kinetosis) is a common and temporarily incapacitant ailment, manageable with behavioral as well as pharmacological measures.

Objective

To assess the effectiveness and safety of a combination of gamma-aminobutyric acid, glutamic acid, calcium, thiamine, pyridoxine, and cyanocobalamin (Group A) (n = 170) and extract of Zingiber officinale (ginger) (Group B) (n = 165) in the management of chronic complaints consistent with motion sickness.

Methods

Both groups were tested according to the following end points, under self-paired as well as comparative study designs: reduction of ≥20 score points in the total motion sickness assessment questionnaire (MSAQ) score, percentage of patients presenting a reduction of the total MSAQ score, absolute MSAQ score reduction, physician's assessment scores, final overall assessment of study medication, and willingness to continue treatment. Safety was also evaluated.

Results

There was a statistically significant better performance under both study designs for Group A (P = 0.05 using different statistical tests) in all end points. Both regimens were safe, with different neurological and gastrointestinal tolerability outcomes.

Conclusions

Group A and Group B regimens were effective and safe in the management of chronic complaints consistent with motion sickness and the Group A regimen was more effective than Group B.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

γ -氨基丁酸、谷氨酸、钙、硫胺素、吡哆醇和氰钴胺与生姜提取物联合治疗慢性运动病的临床评价

运动病是一种常见的暂时性失能性疾病，可通过行为和药物措施加以控制。目的评价γ -氨基丁酸、谷氨酸、钙、硫胺素、吡哆醇和氰钴胺素(a组)(n = 170)和姜提取物(B组)(n = 165)联合治疗运动病慢性主症的有效性和安全性。方法两组均采用自配对和比较研究设计，根据以下终点进行测试:总晕动病评估问卷(MSAQ)评分降低≥20分、总MSAQ评分降低的患者百分比、绝对MSAQ评分降低、医生评估评分、最终研究药物总体评估和继续治疗的意愿。安全性也进行了评估。结果两种研究设计下，a组在各终点的疗效均有统计学意义上的提高(P = 0.05，采用不同的统计学检验)。两种方案都是安全的，只是神经和胃肠道耐受性结果不同。结论A组和B组治疗运动病慢性主诉有效、安全，且A组治疗效果优于B组。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Therapeutic Research-clinical and Experimental 医学-药学

CiteScore

3.50

自引率

0.00%

发文量

审稿时长

3 months

期刊介绍： We also encourage the submission of manuscripts presenting preclinical and very preliminary research that may stimulate further investigation of potentially relevant findings, as well as in-depth review articles on specific therapies or disease states, and applied health delivery or pharmacoeconomics. CTR encourages and supports the submission of manuscripts describing: • Interventions designed to understand or improve human health, disease treatment or disease prevention; • Studies that focus on problems that are uncommon in resource-rich countries; • Research that is "under-published" because of limited access to monetary resources such as English language support and Open Access fees (CTR offers deeply discounted English language editing); • Republication of articles previously published in non-English journals (eg, evidence-based guidelines) which could be useful if translated into English; • Preclinical and clinical product development studies that are not pursued for further investigation based upon early phase results.